To confirm the dominant role of c-Met on nonclassical monocytes during fibrosis development, we correlated the expression of c-Met on CD16+ immune cells with the NAFLD activity score (NAS) of patient samples. Here, MET is linked to metabolic dysfunction-associated steatotic liver disease.